IPO Journey
CEL SCI CORP
IPO Date: May 13, 2026 · 3 filings tracked
Final Offer Terms
Offer Price
$1.20
Shares Offered
6,000,000
Estimated Proceeds
$7.2M
Expected Listing
May 13, 2026
Underwriters
Led by ThinkEquity LLC
Filing Timeline
1
S-1
April 17, 2026
- Multikine immunotherapy shows a 73% five-year survival rate in target patient groups.
- Potential breakthrough treatment for advanced head and neck cancer.
2
S-1/A
May 1, 2026
- Experimental cancer immunotherapy 'Multikine' shows potential in head and neck cancer treatment
- Phase 3 trial data indicates a 73% five-year survival rate for low PD-L1 patients
Changes from previous filing
- ▸ Final offer price: $3.07 per share
- ▸ Shares offered: 4,885,993
- ▸ Estimated proceeds: $14M
424B4
Final Pricing
May 13, 2026
- Developing Multikine, a novel immunotherapy drug for head and neck cancer
- Unique treatment approach: administered before surgery to stimulate immune response
Changes from previous filing
- ▸ Ticker symbol removed
- ▸ Final offer price: $1.2 per share
- ▸ Shares offered: 6,000,000
- ▸ Estimated proceeds: $7M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.